Anti-leukotrienes coverage coming
Anti-leukotrienes coverage coming
The Food and Drug Administration in December approved the second anti-leukotriene drug, zileuton, for the treatment of asthma. The FDA approved the first, zafirlukast, in September. These drugs represent an important new class of asthma medications. Look for comprehensive coverage of this emerging drug protocol in the April issue of Disease State Management. The Editors
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.